Cerus Corporation (CERS) is an American biotechnology company that specializes in the research, development, and commercialization of technologies in the field of blood transfusion safety. The company was established in 1991 and is currently headquartered in Concord, California. Cerus Corporation provides systems that are used globally for plasma, platelet, and red blood cell system needs in the blood transfusion industry, making the transfusion process safer and more efficient.
The flagship product of Cerus Corporation is the INTERCEPT Blood System. This system is specifically designed for the reduction of pathogens in platelets and plasma. The company also sells the INTERCEPT Blood System for red blood cells. This proprietary system uses a technology called pathogen inactivation, which can prevent the transmission of diseases through transfusions by deactivating viruses, bacteria, parasites, and other harmful organisms. Hence its major contribution to ensuring safety and preventing transfusion-transmitted infections during blood transfusions.
Cerus Corporation conducts a partnership program with blood centers, hospitals, and clinicians throughout the world to apply this technology widely and improve the standard of care in blood transfusion safety. It markets its products globally, with a presence in the United States, Europe, the Middle East, and other international locations. The company focuses on expanding its international presence in high-growth markets to further deliver its products to a broader range of global medical facilities.
In addition to product development, Cerus Corporation also devotes a significant portion of its operations to research and development activity. It collaborates with academic, industry, and government organizations to drive technological advancements in blood safety.
As an organization, Cerus Corporation balances both innovation and responsibility. Amid financial success, the company also holds a commitment to corporate social responsibility. It strives to adhere to ethical business practices while contributing to humanitarian goals. Cerus Corporation is not just in the business of providing safe blood products; it works to raise the standards of blood safety, pushing the boundaries of technology and knowledge to make significant advancements in healthcare globally. The innovation at Cerus Corporation is guided by one core principle: to create a better and safer world.
In conclusion, Cerus Corporation (CERS) stands as an innovator in the biotechnology industry, not just through its groundbreaking products but also through its commitment to health, safety, and corporate social responsibility. It continues to strive in delivering safe, effective solutions in the field of blood transfusion safety while also undertaking a broader role of impacting healthcare on a worldwide spectrum.